Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of DexCom, Inc. NASDAQ: DXCM. In a filing disclosed on April 28th, the Representative disclosed that they had sold between $1,001 and $15,000 in DexCom stock on April 8th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.
Representative Robert Bresnahan, Jr. also recently made the following trade(s):
- Sold $1,001 - $15,000 in shares of Invesco NYSE: IVZ on 4/8/2025.
- Sold $1,001 - $15,000 in shares of Generac NYSE: GNRC on 4/8/2025.
- Sold $15,001 - $50,000 in shares of Occidental Petroleum NYSE: OXY on 4/8/2025.
- Sold $15,001 - $50,000 in shares of Pfizer NYSE: PFE on 4/8/2025.
- Sold $1,001 - $15,000 in shares of QUALCOMM NASDAQ: QCOM on 4/8/2025.
- Sold $1,001 - $15,000 in shares of Best Buy NYSE: BBY on 4/8/2025.
- Sold $1,001 - $15,000 in shares of EOG Resources NYSE: EOG on 4/8/2025.
- Sold $1,001 - $15,000 in shares of CSX NASDAQ: CSX on 4/8/2025.
- Sold $1,001 - $15,000 in shares of Valero Energy NYSE: VLO on 4/8/2025.
- Sold $15,001 - $50,000 in shares of Accenture NYSE: ACN on 4/8/2025.
DexCom Price Performance
Shares of NASDAQ:DXCM traded up $11.36 during trading on Friday, reaching $81.62. The stock had a trading volume of 10,694,799 shares, compared to its average volume of 4,256,454. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $132.26. The stock has a market cap of $32.00 billion, a PE ratio of 57.08, a PEG ratio of 2.30 and a beta of 1.50. The business has a fifty day moving average price of $71.60 and a 200-day moving average price of $76.67.
DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The business had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a return on equity of 30.14% and a net margin of 14.29%. DexCom's quarterly revenue was up 12.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.32 EPS. On average, equities analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.
Institutional Trading of DexCom
Hedge funds have recently modified their holdings of the stock. Watts Gwilliam & Co. LLC purchased a new position in shares of DexCom in the 4th quarter valued at about $3,334,000. Congress Asset Management Co. grew its holdings in DexCom by 5,456.9% during the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock worth $105,529,000 after acquiring an additional 1,332,522 shares in the last quarter. Janney Montgomery Scott LLC increased its position in shares of DexCom by 2,226.6% in the 4th quarter. Janney Montgomery Scott LLC now owns 232,543 shares of the medical device company's stock valued at $18,085,000 after purchasing an additional 222,548 shares during the last quarter. First Hawaiian Bank raised its holdings in shares of DexCom by 556.1% in the 4th quarter. First Hawaiian Bank now owns 23,159 shares of the medical device company's stock valued at $1,801,000 after purchasing an additional 19,629 shares in the last quarter. Finally, Proficio Capital Partners LLC purchased a new stake in shares of DexCom during the 4th quarter worth $5,812,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on the company. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Cfra Research upgraded DexCom to a "hold" rating in a report on Friday, March 21st. Baird R W raised shares of DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Mizuho began coverage on shares of DexCom in a research note on Thursday, April 10th. They set an "outperform" rating and a $85.00 target price on the stock. Finally, Piper Sandler cut their price target on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a report on Friday. Five equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, DexCom presently has an average rating of "Moderate Buy" and a consensus price target of $99.22.
Read Our Latest Stock Analysis on DXCM
Insider Buying and Selling
In other DexCom news, COO Jacob Steven Leach sold 14,076 shares of the firm's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $990,668.88. Following the transaction, the chief operating officer now owns 313,497 shares of the company's stock, valued at approximately $22,063,918.86. This trade represents a 4.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 32,498 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $2,287,209.24. Following the transaction, the chief executive officer now owns 372,029 shares in the company, valued at $26,183,401.02. This represents a 8.03 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 66,926 shares of company stock worth $4,734,384. Corporate insiders own 0.32% of the company's stock.
About Representative Bresnahan
Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election.
Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.
DexCom Company Profile
(
Get Free Report)
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
See Also
Before you consider DexCom, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DexCom wasn't on the list.
While DexCom currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
